Warning letterFinalAllegations, not findingsFederal

FDA warns five online peptide sellers that research use only labels do not make injectable GLP-1s legal

Five FDA warning letters dated August 24, 2026 treat semaglutide, tirzepatide, retatrutide and other injectables sold as research chemicals as unapproved new drugs. The disclaimers did not help, and selling bacteriostatic water alongside made it worse.

Source Aug 24, 2026Briefing Sep 21, 2026Reviewed Sep 21, 2026Next review Mar 21, 2027
01What changed

FDA's Center for Drug Evaluation and Research sent warning letters to Peak Performance Peptides, Peptide Partners, Royal Peptides, NuScience Peptides and Tex Peptides after reviewing their websites in July 2026. Each cites products such as semaglutide, tirzepatide, retatrutide, survodutide, mazdutide, SS-31, PT-141 and tesamorelin as unapproved new drugs under section 505(a).

FDA's footnote does the work: despite research use only and not for human consumption labels, the sites' own descriptions of appetite suppression and glycemic control show the products are intended as drugs for human use, and marketing bacteriostatic water as a solvent provides the means to prepare an injectable. Each firm has fifteen business days to respond. These are allegations, not findings.

02Who this affects
  • Online storefronts selling injectable peptides or GLP-1 analogs under research labels.
  • Pharmacies, telehealth brands and clinics that share a domain, a brand or a supply chain with one.
  • Acquirers with merchants coded as laboratory supply whose catalogs are GLP-1 analogs.

The letters go to non pharmacy storefronts, but the reasoning applies to any website that offers injectable peptides or GLP-1 analogs with research use only labelling.

03Key dates
Source publishedAugust 24, 2026Date on all five letters.
Compliance deadlineNot statedEach firm must respond within 15 business days of receipt.
04Why it matters

The label no longer decides what a product is; the offer does. That is the same question a review of any pharmacy website asks. A pharmacy linked to a research peptide storefront inherits its posture, and a merchant category that says laboratory supply over a catalog of semaglutide is the mismatch that ends merchant accounts.

05What to do now
  1. Compare any research labelled product page you or an affiliate runs against the language these letters cite.
  2. Remove clinical framing from research product descriptions, or remove the products.
  3. Stop bundling bacteriostatic water, syringes or reconstitution guides with research labelled peptides.
06How this relates to certification

Website and Digital Presence. The Website and Digital Presence domain covers the products a pharmacy's public pages offer and the claims made about them. Research use only peptides offered with clinical descriptions fall inside that review.

07Sources
All briefingsRevision 2783c18ae26a

Know where your pharmacy stands before the rules change again.

Certified pharmacies are re-verified nightly against state boards, federal enforcement records and their own websites.

Apply for certification Read the methodology
Back to Regulatory Watch